Search
Trastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. … [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational[A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical … [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605]
Brensocatib
go.drugbank.com/drugs/DB15638Approved[A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813] … Non-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by airway widening, mucus accumulation, and neutrophilic inflammation.
Semaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigational[L34485] The use of semaglutide in weight management is also approved by Health Canada [L39347] and the EMA. … as the first approved drug for such use since 2014.
Afamelanotide
go.drugbank.com/drugs/DB04931Approved[L9092] Despite its relatively recent approval, afamelanotide has been available for use as an orphan drug in both the US and EU since 2008.[L9122,L9125] … [L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer
Categories: Protectives Against UV-Radiation for Systemic UseDaptomycin
go.drugbank.com/drugs/DB00080ApprovedInvestigational[A231384] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing … [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseIxekizumab
go.drugbank.com/drugs/DB11569ApprovedInvestigationalAs IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. … Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing.
Opium
go.drugbank.com/drugs/DB11130ApprovedIllicit[A32175] Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. … During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive.[A32171] Opium is extracted from _Papaver somniferum_, which is more known as poppies.
Echothiophate
go.drugbank.com/drugs/DB01057ApprovedInvestigationalA potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
Balsam of Peru
go.drugbank.com/drugs/DB11482ApprovedNutraceuticalVet approved[L2879] By Health Canada, the balsam of Peru is approved by the use of over-the-counter combination products and it is currently approved in veterinary products. … It is constituted by a mixture of substances from which the major components are benzyl cinnamate and [DB00676].
Mixtures: Test Thin-Layer Rapid Use Patch Test